(N-stearyl, norleucine17) VIP hybrid inhibits the growth of pancreatic cancer cell lines |
| |
| Authors: | Zia H Leyton J Casibang M Hau V Brenneman D Fridkin M Gozes I Moody T W |
| |
| Affiliation: | Cell and Cancer Biology Dept., Medicine Branch, National Cancer Institute, Rockville, MD 20850, USA. |
| |
| Abstract: | The effects vasoactive intestinal peptide (VIP) antagonists were investigated on pancreatic cancer cell lines. (N-Stearyl, Norleucine17) VIP hybrid ((SN)VIPhyb) inhibited 125I-VIP binding to human Capan-2 cells with an IC50 value of 0.01 microM whereas VIP hybrid had an IC50 value of 0.2 microM. By RT-PCR and Northern blot, VPAC1 receptor mRNA was detected in CAPAN-2 cells. One microM (SN)VIPhyb and 10 microM VIPhyb inhibited the ability of 30 nM VIP to elevate cyclic AMP and increase c-fos mRNA. (SN)VIPhyb, 1 microM inhibited the clonal growth of CAPAN-2 cells in vitro. In vivo, (SN)VIPhyb (10 microg/day s.c.) inhibited CAPAN-2 xenograft growth in nude mice. These results indicate that (SN)VIPhyb is a pancreatic cancer VPAC receptor antagonist. |
| |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ |
|
